NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT05593094 2026-02-25
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06686394 2026-02-13
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04588545 2026-02-09
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT05150691 2026-01-28
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT05256745 2025-12-24
RAGE
Georgetown University
Phase 1/2 Recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT03304080 2025-07-18
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting